Cardiac autonomic neuropathy (CAN) is a frequently underdiagnosed complication of conditions such as diabetes, Parkinson disease, and other neurological disorders. It arises from damage to the autonomic nerve fibers that innervate the heart and blood vessels, leading to impaired regulation of heart rate and blood pressure. Early and accurate diagnosis is critical because CAN increases the risk of arrhythmias, silent myocardial ischemia, orthostatic hypotension, and even sudden cardiac death. This article provides an in-depth look at the standard tests and procedures used to diagnose CAN, how they work, what to expect, and how to interpret their results.

What Is Cardiac Autonomic Neuropathy?

Cardiac autonomic neuropathy is a subtype of autonomic neuropathy that specifically affects the autonomic nervous system’s control over the cardiovascular system. The autonomic nervous system is composed of the sympathetic and parasympathetic branches, and CAN typically involves dysfunction of both branches. Over time, hyperglycemia, oxidative stress, and microvascular damage in conditions like diabetes lead to progressive degeneration of these nerve fibers. Even in non-diabetic populations, CAN can result from autoimmune diseases, amyloidosis, alcohol misuse, or idiopathic causes. The clinical consequences are wide ranging: patients may experience resting tachycardia, exercise intolerance, orthostatic hypotension (a drop in blood pressure upon standing), and a blunted heart rate response to activity. Recognizing these signs early through proper diagnostic testing can guide interventions that may slow progression and reduce adverse outcomes.

Why Accurate Diagnosis Matters

A correct diagnosis of CAN is not only about naming the condition but also about quantifying its severity to inform treatment decisions. Mild CAN may be managed with lifestyle modifications, such as increased fluid and salt intake for orthostatic hypotension, while more advanced cases might require medications like midodrine or fludrocortisone. Additionally, identifying CAN can help stratify a patient’s cardiovascular risk; those with CAN have a higher likelihood of silent ischemia and should undergo more vigilant cardiac screening. Diagnostic testing also helps rule out other causes of symptoms like dizziness or palpitations, such as cardiac arrhythmias, deconditioning, or medication side effects. Without objective testing, early CAN may be missed because symptoms can be subtle or absent. Therefore, a structured evaluation using validated autonomic tests is the cornerstone of management.

Key Autonomic Tests for Cardiac Autonomic Neuropathy

Several standardized, noninvasive tests are used to assess the integrity of the autonomic control of the cardiovascular system. These tests are often performed in a specialized autonomic laboratory or in a cardiology or neurology clinic. The most common battery includes heart rate variability (HRV) testing, tilt table testing, deep breathing tests, and the Valsalva maneuver. Additional procedures like sudomotor testing and cardiac imaging may be used to complement the evaluation.

1. Heart Rate Variability (HRV) Test

Heart rate variability refers to the normal variation in the time interval between consecutive heartbeats. A healthy autonomic nervous system produces beat-to-beat changes that are influenced by respiration, blood pressure fluctuations, and other physiological rhythms. CAN reduces this variability because the damaged nerves cannot modulate the heart rate appropriately. The HRV test is usually performed with the patient at rest, breathing normally, while an electrocardiogram (ECG) records the R-R intervals. The data are then analyzed using time-domain, frequency-domain, and nonlinear methods. Time-domain measures such as the standard deviation of normal-to-normal intervals (SDNN) and the root mean square of successive differences (RMSSD) reflect overall autonomic modulation. Frequency-domain analysis separates the variability into high-frequency (HF) power, which reflects parasympathetic activity, and low-frequency (LF) power, which reflects a mix of sympathetic and parasympathetic inputs. A reduced SDNN and diminished HF power are hallmark findings in CAN. The test is noninvasive, takes about 10–20 minutes, and requires that the patient avoid caffeine, alcohol, and smoking for a few hours beforehand.

2. Tilt Table Test

The tilt table test evaluates the autonomic response to postural change. The patient lies on a motorized table that can be tilted from a horizontal to an upright position (typically 60–80 degrees). Blood pressure and heart rate are monitored continuously through a cuff or, ideally, via a beat-to-beat finger plethysmograph. The table is tilted for a defined period (usually 10–45 minutes) while the patient is observed for symptoms such as dizziness, presyncope, or syncope. In a healthy individual, upright tilt causes a slight increase in heart rate and diastolic blood pressure, with stability of systolic blood pressure. In CAN patients, the test may reveal orthostatic hypotension (a fall in systolic blood pressure of at least 20 mmHg or diastolic of 10 mmHg within 3 minutes of standing) and, in some cases, neurally mediated syncope. The test can also detect autonomic failure by showing an inadequate heart rate increase in response to hypotension. It is safe when performed under medical supervision, though some patients may experience transient symptoms. Contraindications include uncontrolled hypertension, severe aortic stenosis, or pregnancy.

3. Deep Breathing Test

This test specifically probes parasympathetic function by assessing the heart rate response to controlled respiration. The patient is instructed to breathe deeply at a fixed rate, commonly 6 breaths per minute (5 seconds in, 5 seconds out). The difference between the maximum and minimum heart rate during each respiratory cycle is measured. Under normal circumstances, the heart rate increases during inhalation and decreases during exhalation — a phenomenon called respiratory sinus arrhythmia. In CAN, this variation is blunted. A decreased expiration-to-inspiration (E:I) ratio or a low average heart rate range (less than 10–15 beats per minute) suggests impaired parasympathetic nerve function. The test is simple, noninvasive, and can be performed in an office setting with an ECG. It is important that the patient is comfortable and not hyperventilating. Results can be influenced by age, fitness level, and medications such as beta-blockers.

4. Valsalva Maneuver

The Valsalva maneuver involves forced exhalation against a closed airway (e.g., blowing into a pressure gauge at 40 mmHg for 15 seconds). This creates a transient increase in intrathoracic pressure, followed by complex cardiovascular reflexes. The normal response occurs in four phases: phase I (brief pressure rise), phase II (fall in blood pressure with reflex tachycardia), phase III (further drop upon release), and phase IV (overshoot of blood pressure above baseline due to continued vasoconstriction). The Valsalva ratio — the highest heart rate during the maneuver divided by the lowest heart rate after release — is a measure of overall baroreflex function. In CAN, the vagally mediated bradycardia in phase IV is lost, leading to a prolonged return to baseline and a decreased Valsalva ratio. A ratio below 1.2–1.4 is often considered abnormal, indicating autonomic neuropathy. The Valsalva maneuver is a reliable test of both sympathetic and parasympathetic pathways but requires patient cooperation and careful coaching. It should be avoided in patients with proliferative retinopathy, recent myocardial infarction, or elevated intracranial pressure.

5. Quantitative Sudomotor Axon Reflex Test (QSART)

While not a direct measure of cardiac autonomic function, QSART evaluates the integrity of postganglionic sympathetic cholinergic fibers that innervate sweat glands. Because autonomic neuropathy is often a diffuse process, abnormalities in sudomotor function can indicate generalized autonomic dysfunction that includes cardiac involvement. The test involves delivering a low-level electrical current to the skin using a special capsule filled with acetylcholine. The current stimulates the local sweat glands, and the resulting sweat output is measured. A reduced or absent response suggests nerve damage. QSART is typically performed on the forearm, leg, and foot. It complements the cardiovascular tests by providing objective evidence of peripheral autonomic neuropathy. The test is noninvasive but may cause a tingling sensation or mild discomfort.

Additional Diagnostic Procedures

In some cases, the standard autonomic battery may be insufficient to make a definitive diagnosis or to assess the full impact of CAN. Additional procedures can provide deeper insight and help rule out other conditions.

Cardiac Imaging

Advanced imaging techniques such as myocardial perfusion scintigraphy with 123I-metaiodobenzylguanidine (MIBG) can directly visualize sympathetic nerve endings in the heart. MIBG is a norepinephrine analog that is taken up by sympathetic nerve terminals; reduced uptake indicates denervation. This technique is especially useful in detecting early CAN even before symptoms appear. Another emerging modality is cardiac PET imaging with 11C-hydroxyephedrine, which provides quantitative data on sympathetic nerve density. However, these imaging studies are expensive, not widely available, and usually reserved for research or complex cases. Echocardiography and stress testing are also used to evaluate the functional consequences of CAN, such as diastolic dysfunction or exercise intolerance.

Blood Tests

Although no blood test can directly diagnose CAN, certain laboratory results support the diagnosis or identify underlying causes. Hemoglobin A1c is essential in diabetic patients to assess glycemic control, which correlates with neuropathy risk. Additional tests may include thyroid function, vitamin B12 levels, autoimmune markers (such as antinuclear antibody, anti-SSA/SSB), and tests for amyloidosis or celiac disease. These help differentiate CAN from other neuropathies or conditions that mimic autonomic dysfunction.

24-Hour Holter Monitoring

Holter monitoring records heart rhythm over a full day, allowing analysis of heart rate variability patterns over 24 hours. This ambulatory method captures the response to normal daily activities, sleep, and stressors. Time-domain measures like SDNN over 24 hours are predictive of cardiovascular risk and autonomic function. Holter monitoring is particularly helpful when CAN is suspected based on symptoms like unexplained syncope or palpitations, as it can document bradyarrhythmias or tachyarrhythmias that may be secondary to autonomic imbalance. It is noninvasive and widely available.

Preparing for Autonomic Testing

Proper preparation is essential for accurate results. Patients should be advised to avoid heavy meals, caffeine, alcohol, and tobacco for at least 4–6 hours before testing. Certain medications that affect heart rate or blood pressure, such as beta-blockers, calcium channel blockers, and anticholinergic drugs, may need to be withheld for 24–48 hours under a doctor’s guidance. Discontinuing medications abruptly can be dangerous, so this must be done only with medical approval. Patients should also wear comfortable clothing and avoid strenuous exercise on the day of the test. The testing environment should be quiet, temperature-controlled, and free from distractions to minimize extraneous influences on autonomic tone. The technician or clinician will explain each test beforehand to reduce anxiety, as emotional stress can confound results.

Interpreting Test Results

Diagnosis of CAN is not based on a single test but on a composite of findings. Many laboratories use a scoring system such as the Ewing battery, which assigns points based on the results of HRV, deep breathing, Valsalva, tilt table, and blood pressure responses. A normal composite score indicates intact autonomic function; borderline or abnormal scores suggest CAN of varying severity. For example, an SDNN below 50 ms is often considered severely depressed, while a Valsalva ratio less than 1.2 is abnormal. Age and baseline heart rate must be considered because HRV naturally declines with age. It is also important to correlate test results with the patient’s symptoms. A patient with marked orthostatic hypotension on tilt table testing and reduced HRV likely has definitive CAN, whereas minor abnormalities in a young asymptomatic person may require monitoring rather than immediate intervention. Clinicians use standardized reference ranges, but interpretation should always be individualized, taking into account the patient’s medical history and concurrent medications.

Limitations and Considerations

While autonomic testing is powerful, it has limitations. Many of the standard tests rely on patient cooperation (e.g., deep breathing, Valsalva). Patients who are unable to follow commands or who have respiratory conditions may not produce valid results. Results can also be influenced by training effects; athletes may have higher HRV that masks early neuropathy. Furthermore, CAN can be patchy in its distribution, so normal results on one test do not entirely rule out the condition. The tests assess primarily large-fiber autonomic nerves, but small-fiber neuropathy may be missed unless additional tests like skin biopsies are done. Additionally, there is no single gold standard for diagnosing CAN; the combination of tests provides the best sensitivity and specificity. Researchers continue to develop new techniques, such as pupillometry, neurotransmitter imaging, and continuous glucose monitoring, to refine diagnosis. Despite these limitations, the current testing battery remains a cornerstone of clinical evaluation and is endorsed by major societies such as the American Diabetes Association and the American Autonomic Society.

Who Should Be Tested?

Screening for CAN is recommended for all patients with longstanding type 1 or type 2 diabetes (usually after 5 years), especially those with other diabetic complications such as retinopathy, nephropathy, or peripheral neuropathy. Also, individuals with unexplained syncope, orthostatic hypotension, resting tachycardia, or exercise intolerance should be considered for testing, even in the absence of diabetes. Patients with known autonomic dysfunction from conditions like Parkinson disease, multiple system atrophy, or amyloidosis should undergo baseline and periodic follow-up CAN evaluation. The decision to test should be based on clinical suspicion and the potential to alter management. In asymptomatic but high-risk populations, screening can detect subclinical CAN that may prompt tighter glycemic control or early cardiovascular risk reduction.

Conclusion

Diagnosing cardiac autonomic neuropathy requires a thoughtful combination of clinical history, physical examination, and specialized autonomic testing. The heart rate variability test, tilt table test, deep breathing test, Valsalva maneuver, and sudomotor testing form the core of the diagnostic workup. Additional procedures like cardiac MIBG imaging, Holter monitoring, and targeted blood tests can provide further clarity. Early and accurate diagnosis of CAN can lead to interventions that improve symptoms, reduce hospitalizations, and potentially prolong life. If you or someone you care about experiences symptoms suggestive of autonomic dysfunction, consult a healthcare professional such as a cardiologist or neurologist with expertise in autonomic disorders. For further reading, consider trusted resources like the Mayo Clinic and the American Heart Association.